Managing mycetoma: Guidelines for best practice

Expert Review of Dermatology

Volumn 8, Issue 3, 2013, Pages 301-307

  Fahal, Ahmed Hassan ^a   Elkhawad, Abdalla Omer ^b  

^a UNIVERSITY OF KHARTOUM   (Sudan)

^b UNIVERSITY OF MEDICAL SCIENCES AND TECHNOLOGY   (Sudan)

Author keywords

actinomycetoma; eumycetoma; guidelines; management; mycetoma; protocols; treatment

Indexed keywords

AMIKACIN; ANTIFUNGAL AGENT; CARBAPENEM; CIPROFLOXACIN; COTRIMOXAZOLE; IMIPENEM; ITRACONAZOLE; KETOCONAZOLE; LINEZOLID; MEROPENEM; MOXIFLOXACIN; NEMONOXACIN; PYRIMETHAMINE; RIFAMPICIN; STREPTOMYCIN; SULFADOXINE; TIGECYCLINE;

ACTINOMYCETOMA; AMPUTATION; ANEMIA; ANTIBIOTIC SENSITIVITY; AWARENESS; COMPUTER ASSISTED TOMOGRAPHY; COUNTER IMMUNOELECTROPHORESIS; DEBRIDEMENT; DIAGNOSTIC ACCURACY; DRUG SAFETY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EUMYCETOMA; GYNECOMASTIA; HEALTH CARE PERSONNEL; HEALTH EDUCATION; HUMAN; INCIDENCE; INFECTION RESISTANCE; INFECTION SENSITIVITY; KIDNEY DISEASE; LIBIDO DISORDER; LIVER DISEASE; LIVER TOXICITY; MYCETOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; SKIN DISCOLORATION; SOCIOECONOMICS; TRAINING; TREATMENT OUTCOME; ULCER; XEROSTOMIA;

EID: 84878732848     PISSN: 17469872     EISSN: 17469880     Source Type: Journal    
DOI: 10.1586/edm.13.31     Document Type: Review

References (56)

1. Fahal AH, Hassan MA. Mycetoma. Br. J. Surg. 79(11), 1138-1141 (1992).
2. Fahal AH. Mycetoma: a thorn in the flesh. Trans. R. Soc. Trop. Med. Hyg. 98(1), 3-11 (2004).
3. Fahal AH. Mycetoma. Khartoum Med J. 4(1), 514-523 (2011).
4. Fahal AH. Mycetoma. In: Tropical Infectious Diseases: Principles, Pathogens and Practice (3rd Edition). Guerrant RL, Walker DH, Weller PF (Eds). Saunders-Elsevier, PA, USA, 234-239 (2010).
5. Mahgoub ES, Murray IG. Mycetoma. Heinemann, London, UK, 1-50 (1973).
6. Fahal AH. Mycetoma in Williams, Bulstrode, O'Connell, Bailey and Love's Short Practice of Surgery 26E (26th Edition), Oxford University Press, Oxford, UK, 64-68 (2013).
7. Hay RJ, Mackenzie DW. Mycetoma (madura foot) in the United Kingdom - a survey of forty-four cases. Clin. Exp. Dermatol. 8(5), 553-562 (1983).
8. Lopez Martinez RL, Mendez Tovar J, Lavalle P, Welsh O, Saul A, Macotela Ruiz E. Epidemiology of mycetoma in Mexico: study of 2105 cases. Gac. Med. Mex. 128, 477-481 (1991).
9. Fahal AH. Mycetoma: clinico-pathological monograph. University of Khartoum Press, Republic of Sudan, 23-29 (2006).
10. Fahal AH, Sabaa AH. Mycetoma in children in Sudan. Trans. R. Soc. Trop. Med. Hyg. 104(2), 117-121 (2010).
11. Abbott P. Mycetoma in the Sudan. Trans. R. Soc. Trop. Med. Hyg. 50(1), 11-24; discussion 24 (1956).
12. Maiti PK, Ray A, Bandyopadhyay S. Epidemiological aspects of mycetoma from a retrospective study of 264 cases in West Bengal. Trop. Med. Int. Health 7(9), 788-792 (2002).
13. Ahmed AA, van de Sande WW, Fahal A, Bakker-Woudenberg I, Verbrugh H, van Belkum A. Management of mycetoma: major challenge in tropical mycoses with limited international recognition. Curr. Opin. Infect. Dis. 20(2), 146-151 (2007).
14. Van Belkum A, Fahal AH, van de Sande WW. Mycetoma by Madurella mycetomatis: a completely neglected medico-social dilemma. In: Hot Topics in Infection and Immunity in Children IX. Springer Science & Business Media, NY, USA (2012).
15. Abd El-Bagi MEB, Fahal AH. Mycetoma revisited. Incidence of various radiographic signs. Saudi Med. J. 30(4), 529-533 (2009).
16. AbdBagi ME, Fahal AH, Sheik HE, Abdul Wahab O, Taifoor MK, Osman EM. High incidence of pathological fracture in mycetoma. Trans. R. Soc. Trop. Med. Hyg. 97(5), 582-584 (2003).
17. Fahal AH, Sheikh HE, El Hassan AM. Pathological fracture in mycetoma. Trans. R. Soc. Trop. Med. Hyg. 90(6), 675-676 (1996).
18. Fahal AH, Sheikh HE, El Lider MA, Homeida MA, El Arabi YE, Mahgoub ES. Ultrasonic imaging in mycetoma. Br. J. Surg. 78, 765-766 (1997).
19. EL Shamy ME, Fahal AH, Shakir MY, Homedia MMA. New MRI grading system for the diagnosis and management of mycetoma. Trans. R. Soc. Trop. Med. Hyg. 106(12), 738-742 (2012).
20. EL Hag IA, Fahal AH, Khalil EAG. Fine needle aspiration cytology of mycetoma. Acta Cytologica 40(3), 461-446 (1996).
21. Yousif BM, Fahal AH, Shakir MY. A new technique for the diagnosis of mycetoma using fixed blocks of aspirated material. Trans. R. Soc. Trop. Med. Hyg. 104(1), 6-9 (2010).
22. Ahmed AO, Mukhtar MM, Kools-Sijmons M et al. Development of a species-specific PCRRFLP procedure for the identification of Madurella mycetomatis. J. Clin. Microbiol. 37(10), 3175-3178 (1999).
23. Gumaa SA, Mahgoub ES. Evaluation of the complement fixation test in diagnosis of actinomycetoma. J. Trop. Med. Hyg. 76(6), 140-142 (1973).
24. Gumaa SA, Mahgoub ES. Counterimmunoelectrophoresis in the diagnosis of mycetoma and its sensitivity as compared to immunodiffusion. Sabouraudia 13(3), 309-315 (1975).
25. El Hassan AM, Fahal AH, EL Hag IA, Khalil EAG. The pathology of mycetoma: light microscopic and ultrastructural features. Sudan Med. J. 32, 23-45 (1994).
26. Fahal AH. The management of mycetoma. Post-Grad. Caribbean 16(4), 229-232 (2000).
27. Fahal AH. Management of mycetoma. Expert Rev. Dermatol. 5(1), 87-93 (2010).
28. Estrada R, Chávez-López G, Estrada-Chávez G, López-Martínez R, Welsh O. Eumycetoma. Clin. Dermatol. 30(4), 389-396 (2012).
29. Mahgoub ES, Gumaa SA. Ketoconazole in the treatment of eumycetoma due to Madurella mycetomii. Trans. R. Soc. Trop. Med. Hyg. 78(3), 376-379 (1984).
30. Zein HA, Fahal AH, Mahgoub el S, El Hassan TA, Abdel-Rahman ME. Predictors of cure, amputation and follow-up dropout among patients with mycetoma seen at the Mycetoma Research Centre, University of Khartoum, Republic of Sudan. Trans. R. Soc. Trop. Med. Hyg. 106(11), 639-644 (2012).
31. Fahal AH, Rahman IA, El Hassan AM, Rahman ME, Zijlstra EE. The safety and efficacy of itraconazole for the treatment of patients with eumycetoma due to Madurella mycetomatis. Trans. R. Soc. Trop. Med. Hyg. 105(3), 127-132 (2011).
32. Ahmed AO, van de Sande WW, van Vianen W et al. In vitro susceptibilities of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-Bis(2-methoxy-4-nitro-5- sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay. Antimicrob. Agents Chemother. 48(7), 2742-2746 (2004).
33. Belkum A, Fahal AH, van de Sande WWJ. In vitro susceptibility of Madurella mycetomatis to posaconazole and terbinafine. Antimicrob. Agents Chemother. 55(4), 1771-1773 (2011).
34. Kloezen W, Meis JF, Curfs-Breuker I, Fahal A, van de Sande WWJ. In vitro antifungal activity of isavuconazole to Madurellamycetomatis. Antimicrob. Agents Chemother. 56(11), 6054-6056 (2012).
35. van de Sande WW, de Kat J, Coppens J et al.. Melanin biosynthesis in Madurella mycetomatis and its effect on susceptibility to itraconazole and ketoconazole. Microbes Infect. 9, 1114-1123 (2007).
36. Konishi M, Yonekawa S, Nakagawa C et al. [Case of Scedosporium apiospermum cutaneous soft tissue infection treated with voriconazole]. Kansenshogaku Zasshi. 82(2), 82-85 (2008).
37. Cuenca-Estrella M, Alastruey-Izquierdo A, Alcazar-Fuoli L et al. In vitro activities of double combinations of antifungal agents against Scedosporium apiospermum and Scedosporium prolificans. Antimicrob. Agents Chemother. 52(3), 1136-1139 (2008).
38. Scheinfeld N. A review of the new antifungals: posaconazole, micafungin, and anidulafungin. Drugs Dermatol. 6(12), 1249-1251 (2007).
39. Loo DS. Systemic antifungal agents: an update of established and new therapies. Adv. Dermatol. 22, 101-124 (2006).
40. Welsh O, Vera-Cabrera L, Welsh E, Salinas MC. Actinomycetoma and advances in its treatment. Clin. Dermatol. 30(4), 372-381 (2012).
41. Mahgoub ES. Treatment of actinomycetoma with sulphamethoxazole plus trimethoprim. Am. J. Trop. Med. Hyg. 21(3), 332-335 (1972).
42. Welsh O, Sauceda E, Gonzalez J, Ocampo J. Amikacin alone and in combination with trimethoprim-sulfamethoxazole in the treatment of actinomycotic mycetoma. J. Am. Acad. Dermatol. 17(3), 443-448 (1987).
43. Damle DK, Mahajan PM, Pradhan SN et al. Modified Welsh regimen: a promising therapy for actinomycetoma. J. Drugs Dermatol. 7(9), 853-856 (2008).
44. Vera-Cabrera L, Daw-Garza A, Said-Fernández S et al. Therapeutic effect of a noveloxazolidinone, DA-7867, in BALB/c mice infected with Nocardia brasiliensis. PLoSNegl. Trop. Dis. 10, 2(9), e289 (2008).
45. Chacon-Moreno BE, Welsh O, Cavazos-Rocha N et al. Efficacy of ciprofloxacin and moxifloxacin against Nocardia brasiliensis in vitro and in an experimental model of actinomycetoma in BALB/c mice. Antimicrob. Agents Chemother. 53(1), 295-297 (2009).
46. Gomez A, Saul A, Bonifaz A, Lopez M. Amoxicillin and clavulanic acid in the treatment of actinomycetoma. Int. J. Dermatol. 32(3), 218-220 (1993).
47. Bonifaz A, Flores P, Saúl A, Carrasco-Gerard E, Ponce RM. Treatment of actinomycetoma due to Nocardia spp. with amoxicillin-clavulanate. Br. J. Dermatol. 156(2), 308-311 (2007).
48. Fuentes A, Arenas R, Reyes M, Fernández RF, Zacarías R. [Actinomycetoma and Nocardia sp. Report of five cases treated with imipenem or imipenem plus amikacin]. Gac. Med. Mex. 142(3), 247-252 (2006).
49. Yazawa K, Mikami Y, Ohashi S, Miyaji M, Ichihara Y, Nishimura C. In-vitro activity of new carbapenem antibiotics: comparative studies with meropenem, L-627 and imipenem against pathogenic Nocardia spp. J. Antimicrob. Chemother. 29(2), 169-172 (1992).
50. Lai CC, Tan CK, Lin SH et al. Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species. J. Antimicrob. Chemother. 64(1), 73-78 (2009).
51. Cercenado E, Marín M, Sánchez-Martínez M, Cuevas O, Martínez-Alarcón J, Bouza E. In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods. Antimicrob. Agents Chemother. 51(3), 1102-1104 (2007).
52. Espinoza-González NA, Welsh O, de Torres NW et al. Efficacy of DA-7218, a new oxazolidinone prodrug, in the treatment of experimental actinomycetoma produced by Nocardia brasiliensis. Molecules 13(1), 31-40 (2008).
53. Ameen M, Arenas R. Emerging therapeutic regimes for the management of mycetomas. Expert Opin. Pharmacother. 9(12), 2077-2085 (2008).
54. Ameen M, Arenas R. Developments in the management of mycetomas. Clin. Exp. Dermatol. 34(1), 1-7 (2009).
55. El Hassan AM, Mahgoub ES. Lymph node involvement in mycetoma. Trans. R. Soc. Trop. Med. Hyg. 66(1), 165-169 (1972).
56. Fahal AH. Evidence-Based Guidelines for the Management of Mycetoma Patients, 2001, at the Mycetoma Research Center, University of Khartoum. www.mycetoma.edu.sd